Minerva Neurosciences, Inc: Minerva Neurosciences Submits New Drug Application to FDA for Roluperidone for the Treatment of Negative Symptoms in Patients with Schizophrenia

WALTHAM, Mass., Aug. 22, 2022(Nasdaq: NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central nervous system (CNS) disorders, today announced that the

Related Keywords

United States ,Helen Shik ,Remy Luthringer ,Frederick Ahlholm ,Minerva Neurosciences ,Exchange Commission ,Exchange Commission On ,Shik Communications ,Drug Administration ,Minerva Neurosciences Inc ,Nasdaq ,New Drug Application ,Executive Chairman ,Chief Executive ,Open Label ,Negative Syndrome Scale ,Social Performance Scale ,Clinical Global Impression ,Structured Model Negative ,Negative Symptoms Factor Score ,Double Blind ,Private Securities Litigation Reform Act ,Quarterly Report ,Aminerva ,Neurosciences ,Ubmits ,Drug ,Application ,Roluperidone ,Treatment ,Negative ,Symptoms ,Patients ,Schizophrenia ,